Skip to content
Disclosery

GREAT POINT PARTNERS LLC

Follow

13F filer, CIK 1281446, Greenwich, CT

GREAT POINT PARTNERS LLC reported $242,495,757 across 30 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14. Its ten largest share positions make up 64.04% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001814554-25-000164

Period
2025-09-30
Reported value
$242M
Holdings
30
Top 10 weight
64.04%
New
12
Sold out
8

Largest buys vs the previous quarter

SecurityShares changeApprox. value
NKTRnew+300,000$17.1M
SLNOnew+225,000$15.2M
ASNDnew+75,000$14.9M
APGEnew+304,000$12.1M
DNTHnew+265,803$10.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ABVXreduced-1,141,617-$96.9M
IONSreduced-420,000-$27.5M
LEGNreduced-236,540-$7.71M
AKBAexited-1,985,915-$7.23M
EOLSexited-720,118-$6.63M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001814554-25-000164, largest first. % of portfolio is the value over $239,520,840, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,811,996 shares; 2025Q2: 2,000,000 shares; 2025Q3: 1,700,000 shares 1,700,000$23.1M9.65%-300,000Timeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 621,894 shares; 2025Q1: 833,042 shares; 2025Q2: 3,033,462 shares; 2025Q3: 2,451,809 shares 2,451,809$23M9.62%-581,653Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 300,000 shares 300,000$17.1M7.13%newTimeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,263,672 shares; 2024Q4: 3,170,194 shares; 2025Q1: 3,170,194 shares; 2025Q2: 3,170,194 shares; 2025Q3: 3,815,930 shares 3,815,930$16.5M6.9%+645,736Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 225,000 shares 225,000$15.2M6.35%newTimeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 50,000 shares; 2025Q2: not reported; 2025Q3: 75,000 shares 75,000$14.9M6.23%newTimeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,128,773 shares; 2024Q4: 1,648,523 shares; 2025Q1: 1,638,111 shares; 2025Q2: 1,291,617 shares; 2025Q3: 150,000 shares 150,000$12.7M5.32%-1,141,617Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 304,000 shares 304,000$12.1M5.04%newTimeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 275,000 shares; 2024Q4: 275,000 shares; 2025Q1: 275,000 shares; 2025Q2: not reported; 2025Q3: 265,803 shares 265,803$10.5M4.37%newTimeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 316,000 shares; 2024Q4: 360,000 shares; 2025Q1: 370,000 shares; 2025Q2: 150,000 shares; 2025Q3: 150,000 shares 150,000$8.24M3.44%0Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 375,000 shares; 2025Q2: 262,176 shares; 2025Q3: 500,000 shares 500,000$8.06M3.37%+237,824Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 245,272 shares; 2025Q1: 245,272 shares; 2025Q2: 200,000 shares; 2025Q3: 200,000 shares 200,000$8.03M3.35%0Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,004,291 shares; 2024Q4: 442,761 shares; 2025Q1: 470,964 shares; 2025Q2: 485,859 shares; 2025Q3: 446,814 shares 446,814$7.74M3.23%-39,045Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,200,000 shares 1,200,000$7.08M2.96%newTimeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 300,000 shares; 2025Q1: 300,000 shares; 2025Q2: 300,000 shares; 2025Q3: 300,000 shares 300,000$5.64M2.36%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 498,054 shares; 2025Q3: 632,599 shares 632,599$5.46M2.28%+134,545Timeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 255,000 shares; 2024Q4: 505,007 shares; 2025Q1: 250,000 shares; 2025Q2: 500,000 shares; 2025Q3: 80,000 shares 80,000$5.23M2.19%-420,000Timeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 103,848 shares; 2025Q3: 103,848 shares 103,848$4.93M2.06%0Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,500,000 shares; 2025Q3: 1,500,000 shares 1,500,000$4.91M2.05%0Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,934,982 shares; 2024Q4: 4,683,711 shares; 2025Q1: 4,683,711 shares; 2025Q2: 4,683,711 shares; 2025Q3: 4,683,711 shares 4,683,711$4.54M1.89%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,105 shares 155,105$3.87M1.62%newTimeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 374,679 shares; 2025Q3: 378,594 shares 378,594$3.79M1.58%+3,915Timeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 138,240 shares; 2025Q2: 350,000 shares; 2025Q3: 113,460 shares 113,460$3.7M1.54%-236,540Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 514,659 shares; 2024Q4: 228,803 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 183,330 shares 183,330$3.53M1.47%newTimeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 796,558 shares; 2025Q3: 796,558 shares 796,558$3.47M1.45%0Timeline
SANASANA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 700,000 shares 700,000$2.48M1.04%newTimeline
ABSIABSCI CORPORATIONQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 796,438 shares 796,438$2.42M1.01%newTimeline
PLRXPLIANT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,910,121 shares; 2024Q4: 1,055,000 shares; 2025Q1: 850,000 shares; 2025Q2: 850,000 shares; 2025Q3: 850,000 shares 850,000$1.26M0.53%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
HRMYHARMONY BIOSCIENCES HLDGS IN COMcall85,000$2.34Mnew
CAPRCAPRICOR THERAPEUTICS INC COMMON STOCKput87,700$632Knew

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
AKBAAKEBIA THREAPEUTICS INC1,985,915$7.23Mshares
EOLSEVOLUS INC720,118$6.63Mshares
ACLXARCELLX INC100,000$6.58Mshares
KALVKALVISTA PHARMACEUTICALS INC323,170$3.65Mshares
CNTACENTESSA PHARMACEUTICALS PLC225,000$2.96Mshares
SRRKSCHOLAR ROCK HLDG CORP61,607$2.18Mshares
PROMIS NEUROSCIENCES INCPROMIS NEUROSCIENCES INC2,645,128$1.28Mshares
HELIX ACQUISITION CORP IIHELIX ACQUISITION CORP II29,381$312Kshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001814554-25-000164 base2025-11-14acceptance time not in the bulk data set